Benzinga | Aug 31, 2021 07:12AM EDT

Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot

* GlaxoSmithKline Plc (NYSE:GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co.

* The study will enroll 4,000 participants and compare the shot to Oxford University - AstraZeneca Plc (NASDAQ:AZN).

* The trial will test SK's protein-based vaccine candidate, GBP510, in combination with Glaxo, providing an adjuvant that can enhance the response to vaccines.

* Results from the Phase 3 study are expected in 1H of 2022, after which, subject to positive outcomes and regulatory approval, the vaccine is expected to be supplied at scale worldwide through the COVAX facility.

* Glaxo has been developing adjuvants for other vaccines developed by Sanofi SA (NASDAQ:SNY) and Medicago.

* Related Content: Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine

* Also Read: GSK Kick Starts Late-Stage Study With Medicago-Partnered COVID-19 Vaccine

* GSK is also working with CureVac BV (NASDAQ:CVAC) to jointly develop next-generation mRNA vaccines for COVID-19 to tackle multiple emerging variants in one vaccine.

* Related: GlaxoSmithKline, CureVac In Pact To Develop Vaccines For COVID-19 Variants

* Price Action: GSK shares are down 0.81% at $40.58 during the premarket session on the last check Tuesday.

* Photo by hakan german from Pixabay